Anti-IgE- and anti-IgA-induced eosinophil migration in atopics and healthy volunteers.
Rihoux
J P
JP
UCB Pharmaceutical Sector, Belgium.
Melac
M
M
Henocq
E
E
D000293:Adolescent; D000328:Adult; D002465:Cell Movement; D004311:Double-Blind Method; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007073:Immunoglobulin E / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology*; D008297:Male; D011897:Random Allocation
D006634:Histamine H1 Antagonists; D007074:Immunoglobulin G; D007073:Immunoglobulin E